Therefore, it is well documented that comprehensive ctDNA detection in early-stage KRAS-mutant NSCLC and repeated postsurgical MRD monitoring could be used for the follow-up, improving the outcome of this subset of patients. This evidence concerns the gene KRAS and non-small cell lung carcinoma.